Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (Lichtiger index) (4 weeks) · Patients with active mild to moderate ulcerative colitis
1 finding from 1 review
Quality of life · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics showed no clear difference in clinical relapse (6 months) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (partial Mayo score) (60 days) · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review
Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people in remission or with mildly activeulcerative colitis
1 finding from 1 review